


RECEIVED
MAY 16 2002

LIST OF ART CITED BY APPLICANT				ATTY. DOCKET NO.		SERIAL NO.	
				Old: 114205.2402		09/955,174	
				New: 215101.02402			
				APPLICANT William G.KERR.			
				FILING DATE September 19, 2001		GROUP 1614	
TECH CENTER 1600/2900							
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
g3	6,090,621	18 Jul 2000	Kavanaugh et al.				
	4,603,112	29 Jul 1986	Paoletti et al.				
	4,769,330	6 Sep 1988	Paoletti et al.				
	5,017,487	21 May 1991	Stunnenberg et al.				
	4,777,127	11 Oct 1988	Suni et al.				
	5,166,057	24 Nov 1992	Palese et al.				
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes No	
g3	WO 97/10252A1	13 Sep 1996	Rohrschneider, L.R.				
	WO 97/12039A2	27 Sep 1996	Krystal, G.				
	WO 89/01973	9 Mar 1989	Panicali, D. et al.				
	GB 2,200,651	14 Sep 1988	Al-Sumidaie, A.M.K.				
	EP 0,345,242	6 Dec 1989	Jacobs, E. et al.				
	WO 91/02805	7 Mar 1991	Chang, S.M.W. et al.				
	EP 0 440,219	7 Aug 1991	Billeter, M.A. et al.				
	WO 92/06693	30 Apr 1992	Taylor, J.D.				
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
g3	Kapeller et al., "Phosphatidylinositol 3-Kinase," Bioessays; 16, 1994: 565-76.						
	Stephens, L.R. et al., "Agonist-stimulated synthesis of phosphatidylinositol(3,4,5)-trisphosphate: a new intracellular signalling system?" Biochim. BiophysActa; 1179, 1993: 27-75.						
	Hawkins P.T. et al., "Platelet-derived growth factor stimulates synthesis of PtdIns(3,4,5)P ₃ by activating a PtdIns(4,5)P ₂ 3-OH kinase," Nature; 358, 1992: 157-910.						
	Klippel A. et al., "Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways," Molecular and Cellular Biology, vol. 16, no. 8, 1996: 4117-27.						
	Helgason, C.D. et al., "Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span," Genes & Dev., vol. 12, no. 11, 1998: 1610-20.						
	Huber, M. et al., "The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation," Proc. Natl. Acad. Sci. U.S.A., vol. 95, no. 19, 1998: 11330-35.						
	Liu, Q. et al., "SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation any myeloid cell-survival," Genes & Dev., vol. 13, no. 7, 1999: 789-91						
	Liu, Q. et al., "The inositol polyphosphate 5-phosphatase SHIP is a crucial negative regulator of B cell antigen receptor signalling," J. Exp. Med., vol. 188, no. 7, 1998: 1333-42.						

MAY 16 2002

RECEIVED

TECH CENTER 1600/2900

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
Jefferson, A.B. et al., "Properties of type II inositol polyphosphate 5-phosphatase;" J. Biol. Chem. vol. 270, no. 16, 1995: 9370-77.	
Wang, C.Y. et al., "pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse;" PNAS, vol. 84, 1987: 7851.	
Jolly, D., "Viral vector systems for gene therapy;" Cancer Gene Therapy, vol. 1, no. 1, 1994: 51-64.	
Evans, D.J. et al., "An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies;" Nature, vol.339, 1989: 385-88.	
Sabin, A.B. et al., "History of Sabin attenuated poliovirus oral live vaccine strains;" J. of Biol. Standardization, vol. 1, 1973: 115-18.	
Fisher-Hoch, S.P. et al., "Protection of rhesus monkeys from fatal Lassa fever by vaccination with recombinant vaccinia virus containing the Lassa virus glycoprotein gene;" PNAS, vol. 86, 1989: 317-21.	
Moss, B. et al., "Vaccinia virus expression vectors;" Ann. N.Y. Acad. Sci. vol. 569, 1989: 86-103.	
Flexner, C. et al., "Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2;" Vaccine, vol. 8, 1990: 17-21.	
Mulligan, R.C. et al., "Synthesis of rabbit β -globin in cultured monkey kidney cells following infection with a SV40 β -globin recombinant genome;" Nature, vol. 277, 1979: 108-114.	
Luytjes, W. et al., "Amplification, expression, and packaging of a foreign gene by influenza virus;" Cell, vol. 59, 1989: 1107-13.	
McMichael, A.J. et al., "Cytotoxic T-cell immunity to influenza;" N. Eng. J. Med., vol. 309, no. 1, 1983: 13-17.	
Yap, K.L. et al., "Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus;" Nature, vol. 273, 1978: 238-39.	
Berkner, K.L., "Development of adenovirus vectors for the expression of heterologous genes;" BioTechniques, vol. 6, no. 7, 1988: 616-27.	
Rosenfeld, M.A. et al., "Adenovirus-mediated transfer of a recombinant α 1-antitrypsin gene to the lung epithelium in vivo;" Science, vol. 252, 1991: 431-34.	
Kolls, J. et al., "Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer;" PNAS, vol. 91, 1994: 215-19.	
Kass-Eisler, A. et al., "Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo;" PNAS, 90, 1993:11498-502.	
Guzman, R.J. et al., "Efficient and selective adenovirus-mediated gene transfer into vascular neointima;" Circulation, vol. 88, no. 6, 1993:2838-48.	
Guzman, R.J. et al., "Efficient gene transfer into myocardium by direct injection of adenovirus vectors;" Cir. Res. vol. 73, no. 6, 1993: 1202-07.	
Zabner, J. et al., "Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis;" Cell, vol. 75, 1993: 207-16.	
Li, Q. et al., "Assessment of recombinant adenoviral vectors for hepatic gene therapy;" Hum. Gene. Ther., vol. 4, 1993: 403-09.	
Caillaud, C. et al., "Adenoviral vector as a gene delivery system into cultured rat neuronal and glial cells;" Eur. J. Neurosci., vol. 5, 1993: 1287-91.	
Vincent, N. et al., "Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene;" Nat. Genet., vol. 5, 1993: 130-34.	
Jaffe, H.A. et al., "Adenovirus-mediated in vivo gene transfer and expression in normal rat liver;" Nat. Genet., Vol. 1, 1992: 372-78.	
Levrero, M. et al., "Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo;" Gene, vol. 101, 1991: 195-202.	
Samulski, R.J. et al., "Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression;" J. Vir. vol. 63, No. 9, 1989: 3822-3828.	
Mendelson, E. et al., "Expression and rescue of a nonselected marker from an integrated AAV vector;" Virol., Vol. 166, 1988: 154-65.	

Docket No.: PH114205.2402/MZR215101.02402
Customer No. 27160

PATENT/OFFICIAL
Serial No. 09/955,174

TECH CENTER 1600/2900

MAY 16 2002

RECEIVED

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
83	Kit, S., "Recombinant-derived modified-live herpesvirus vaccines;" Immunobiology of Proteins and Peptides V Vaccines: Mechanisms, Design, and Applications, Atassi, M.Z., Ed. Plenum Press, New York, 215, 1989: 219-36.
	Poznansky, M. et al., "Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector;" J. Virol., vol. 65, no. 1, 1991: 532-36.
	Munroe, S.S. et al., "Subgenomic RNA sequence of human astrovirus supports classification of astroviridae as a new family;" J. Vir. Vol. 67, no. 6, 1993: 3611-14.
	Overbaugh, J. et al., "Molecular cloning of a feline leukemia virus that induces fatal immunodeficiency disease in cats;" Science, vol. 239, 1988: 906-10.
	Bender, M.A. et al., "Description and Targeted deletion of 5' hypersensitive site 5 and 6 of the mouse β -globin locus control region;" Blood, 92, 1998:4394-403.
	Lanier, L.L., "NK cell receptors;" Annual Review of Immunology, vol. 16, 1998: 359-93.
	Yokoyama, W.M., "Natural killer cell receptors;" Current Opinion in Immunology, vol. 10, no. 3, 1998: 298-305.
	Koh, C. et al., "Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo;" Blood, vol. 97, no. 10, 2001: 3132-37.
	Ruggeri, L., "Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation;" Blood, vol. 94, no. 1, 1999: 333-39.
EXAMINER	DATE CONSIDERED
83	2-4-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
DC: #4122404v1-114205.2402/15101.02402



RECEIVED
FEB 07 2003
U.S. PATENT & TRADEMARK OFFICE

Approved for use through 10/31/2002 by USPTO/ST/08A (0001)
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/955,174
				Filing Date	September 19, 2001
				First Named Inventor	William G. Kerr
				Art Unit	1614
				Examiner Name	(not yet assigned)
				Attorney Docket Number	USF-T150CX
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
JZ	U1	US-6,025,198	12-15-2000	Bennet et al.	throughout
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			


FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	F1				
	F2				
	F3				
	F4				
	F5				
	F6				
	F7				
	F8				
	F9				
	F10				

Examiner Signature		Date Considered	2-4-04
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

FEB 07 2003

TECH CENTER 1600/2900

PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Copyright Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/955,174
Filing Date	September 19, 2001
First Named Inventor	William G. Kerr
Group Art Unit	1614
Examiner Name	(not yet assigned)
Attorney Docket Number	USF-T150CX

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
J2	R1	AKAGI, KIWAMU et al., Cre-mediated comatic site-specific recombination in mice, Nucleic Acids Research, 1997, 25(9):1766-1773, Oxford University Press.	
	R2	LOTZOVA, E. et al., Prevention of Rejection of Allogeneic Bone Marrow Transplants by NK-1.1 Anti Serum, Transplantation, 1983, 35(5):490-494.	
	R3	HELD, WERNER et al., Transgenic expression of the Ly49A natural killer cell receptor confers class I major histocompatibility complex (MHC)-specific inhibition and prevents bone marrow allograft rejection, Journal of Experimental Medicine, 1996 184(5):2037-2041.	
	R4	GHANSAH, TOMAR et al., The Src homology 2 containing inositol phosphatase is vital for the function and homeostatis of Natural Killer cells, FASEB Journal, March 7, 2001, 15(4):A655.	
	R5	KERR, WILLIAM G. et al., Critical Role for SHIP in engraftment of histo-incompatible stem cells, Oncology Research, 2001, 12:285.	
	R6	GHANSAH, TOMAR et al., A role for the SH2-containing inositol phosphatase in the biology of natural killer cells and stem cells, Activating and Inhibitory Immunoglobulin-like Receptors, 2001, 129-140.	
	R7	WANG, JIA WANG et al., Influence of ZSHIP on the NK Repertoire and Allogeneic Bone Marrow Transplantation, Science, 295(5562):2094-2097.	
	R8	DESPONTS, CAROLINE et al., MHC class I inhibitory receptors on natural killer cells recruit SHIP in an attempt to control cell survival, FASEB Journal, March 20, 2002, 16(4):A706.	
	R9	GHANSAH, TOMAR et al., Target disruption of Src homology 2-containing 5' inositol phosphatase (SHIP) alters PI3K/AKT and MAPK signal transduction pathways in murine natural killer cells, FASEB Journal, March 20, 2002, 16(4):A706	
	R10		
	R11		
	R12		
	R13		

Examiner
SignatureDate
Considered

2-4-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.